PARIS, FRANCE: Nanobiotix, a biotechnology company developing nanotherapeutics for cancer, has announced a global deal with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for its lead drug NBTXR3. NBTXR3 is a potential first-in-class radioenhancer that is being tested in several solid tumor indications, including a global Phase 3 study…
All posts tagged Nanobiotix
Nanobiotix announces key development milestones for 2021 after successful Nasdaq IPO
PARIS: Nanobiotix announced its global development plan for 2021 and beyond. Nanobiotix is a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy and increasing the proportion of patients that respond to immune checkpoint inhibitors. “Following the successful closing of our…